Kumar Sameera S, McGarry Ronald C
Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA, USA.
Department of Radiation Oncology, University of Kentucky, Lexington, KY, USA.
Transl Lung Cancer Res. 2019 Sep;8(Suppl 2):S213-S221. doi: 10.21037/tlcr.2019.09.06.
Stereotactic body radiation therapy (SBRT) is a very effective way to treat early stage non-small cell lung cancer (NSCLC) and small oligometastatic lung lesions with consistently high rates of local control, but both local and regional/distant recurrences still occur. The management of recurrences remains unsettled and may entail repeat SBRT, conventionally fractionated external beam RT (EF-EBRT), chemotherapy or surgery. Most patients with local recurrences [within the initial planning target volume (PTV)] can be salvaged successfully with good cancer specific survival. Nonetheless, proximity of the initial SBRT delivery to organs at risk (ribs, blood vessels, airways) may make retreatment more difficult. With attention to detail and careful patient selection, both surgery and reirradiation can be performed safely and effectively. Strategies for management of regional (nodal) recurrences may require conventional therapies tailored to the patterns of failure. The role of immunotherapy in salvage has not been elucidated as yet. We review here data on the available literature concerning salvage of SBRT lung patients.
立体定向体部放射治疗(SBRT)是治疗早期非小细胞肺癌(NSCLC)和小的寡转移肺病灶的一种非常有效的方法,局部控制率持续很高,但局部和区域/远处复发仍会发生。复发的处理仍未确定,可能需要重复SBRT、传统分割外照射放疗(EF-EBRT)、化疗或手术。大多数局部复发(在初始计划靶区[PTV]内)的患者可以成功挽救,具有良好的癌症特异性生存率。尽管如此,初始SBRT治疗与危及器官(肋骨、血管、气道)的接近度可能使再次治疗更加困难。通过注重细节和仔细选择患者,手术和再照射都可以安全有效地进行。区域(淋巴结)复发的处理策略可能需要根据失败模式定制传统疗法。免疫疗法在挽救治疗中的作用尚未阐明。我们在此回顾有关SBRT肺部患者挽救治疗的现有文献数据。